MX2023010971A - Formulacion de laquinimod para uso ocular. - Google Patents
Formulacion de laquinimod para uso ocular.Info
- Publication number
- MX2023010971A MX2023010971A MX2023010971A MX2023010971A MX2023010971A MX 2023010971 A MX2023010971 A MX 2023010971A MX 2023010971 A MX2023010971 A MX 2023010971A MX 2023010971 A MX2023010971 A MX 2023010971A MX 2023010971 A MX2023010971 A MX 2023010971A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutically acceptable
- formulation
- laquinimod
- ocular use
- agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Ophthalmology & Optometry (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21166691 | 2021-04-01 | ||
| PCT/EP2022/058523 WO2022207773A1 (en) | 2021-04-01 | 2022-03-31 | Laquinimod formulation for ocular use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023010971A true MX2023010971A (es) | 2023-09-27 |
Family
ID=75362492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023010971A MX2023010971A (es) | 2021-04-01 | 2022-03-31 | Formulacion de laquinimod para uso ocular. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20240180819A1 (enExample) |
| EP (2) | EP4461364B1 (enExample) |
| JP (1) | JP2024516929A (enExample) |
| KR (1) | KR20230165260A (enExample) |
| CN (1) | CN117120035A (enExample) |
| AU (1) | AU2022248724A1 (enExample) |
| BR (1) | BR112023018932A2 (enExample) |
| CA (1) | CA3212851A1 (enExample) |
| ES (1) | ES3014261T3 (enExample) |
| IL (1) | IL305997A (enExample) |
| MX (1) | MX2023010971A (enExample) |
| PL (1) | PL4312986T3 (enExample) |
| WO (1) | WO2022207773A1 (enExample) |
| ZA (1) | ZA202309969B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL320428A (en) | 2022-11-04 | 2025-06-01 | Qlaris Bio Inc | Topical ophthalmic administration of cromolyns |
| CN118892446A (zh) * | 2023-04-27 | 2024-11-05 | 维眸生物科技(浙江)有限公司 | 一种含vvn001的眼科组合物 |
| CN119523881A (zh) * | 2024-04-28 | 2025-02-28 | 中国人民解放军海军军医大学第二附属医院 | 一种s100a9抑制剂凝胶剂及其制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6077851A (en) | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
| US20110052678A1 (en) * | 2010-11-05 | 2011-03-03 | Shantha Totada R | Method for treating age related macular degeneration |
| TW201400117A (zh) * | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| US9089562B2 (en) * | 2013-08-28 | 2015-07-28 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
| EP3068395A4 (en) * | 2013-11-15 | 2017-07-12 | Teva Pharmaceutical Industries Ltd. | Treatment of glaucoma using laquinimod |
| US9694003B2 (en) * | 2015-10-15 | 2017-07-04 | Bridge Pharma, Inc. | Formulations and methods for treating high intraocular pressure |
| IL289109B2 (en) * | 2019-06-19 | 2025-10-01 | Tarsus Pharmaceuticals Inc | Isoxazoline formulations against parasites and methods for treating blepharitis |
| KR20220118419A (ko) | 2019-12-19 | 2022-08-25 | 액티브 바이오테크 에이비 | 과도한 혈관신생과 관련된 안구 질병의 치료를 위한 화합물 |
-
2022
- 2022-03-31 PL PL22718720.0T patent/PL4312986T3/pl unknown
- 2022-03-31 US US18/284,284 patent/US20240180819A1/en active Pending
- 2022-03-31 KR KR1020237035464A patent/KR20230165260A/ko active Pending
- 2022-03-31 CA CA3212851A patent/CA3212851A1/en active Pending
- 2022-03-31 ES ES22718720T patent/ES3014261T3/es active Active
- 2022-03-31 CN CN202280022389.2A patent/CN117120035A/zh active Pending
- 2022-03-31 JP JP2023557096A patent/JP2024516929A/ja active Pending
- 2022-03-31 BR BR112023018932A patent/BR112023018932A2/pt unknown
- 2022-03-31 IL IL305997A patent/IL305997A/en unknown
- 2022-03-31 MX MX2023010971A patent/MX2023010971A/es unknown
- 2022-03-31 AU AU2022248724A patent/AU2022248724A1/en active Pending
- 2022-03-31 EP EP24203145.8A patent/EP4461364B1/en active Active
- 2022-03-31 EP EP22718720.0A patent/EP4312986B1/en active Active
- 2022-03-31 WO PCT/EP2022/058523 patent/WO2022207773A1/en not_active Ceased
-
2023
- 2023-10-25 ZA ZA2023/09969A patent/ZA202309969B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022248724A1 (en) | 2023-11-02 |
| KR20230165260A (ko) | 2023-12-05 |
| JP2024516929A (ja) | 2024-04-18 |
| US20240180819A1 (en) | 2024-06-06 |
| PL4312986T3 (pl) | 2025-02-17 |
| BR112023018932A2 (pt) | 2023-10-10 |
| CA3212851A1 (en) | 2022-10-06 |
| EP4312986B1 (en) | 2024-10-23 |
| EP4461364A3 (en) | 2024-11-27 |
| CN117120035A (zh) | 2023-11-24 |
| ZA202309969B (en) | 2025-03-26 |
| EP4312986C0 (en) | 2024-10-23 |
| EP4461364A2 (en) | 2024-11-13 |
| EP4461364B1 (en) | 2026-04-22 |
| EP4312986A1 (en) | 2024-02-07 |
| WO2022207773A1 (en) | 2022-10-06 |
| ES3014261T3 (en) | 2025-04-21 |
| IL305997A (en) | 2023-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202309969B (en) | Laquinimod formulation for ocular use | |
| MX2021007970A (es) | Derivado de 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y uso medico del mismo. | |
| MX2025001619A (es) | Inhibidor de pde4b y uso del mismo | |
| IL248745B (en) | (s)-2-amino-3-methyl butyric acid (r2, r3, rb11)-3 azazobutyl-9,10-dimethoxy-1,3,4,6,711b-hexahydro-h2-pyrido[a-1,2 ] isoquinoline-2-yl ester for use in the treatment of Tardib Discenza | |
| NO20065638L (no) | Formuleringer med kontrollert frigivelse inneholdende vardenafil | |
| EP4397375A3 (en) | Isoxazoline parasiticide formulations and methods for treating blepharitis | |
| US10888552B2 (en) | Treatment of disorders of sexual arousal with local application of agents that increase membrane excitability | |
| MY208983A (en) | Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or its salt | |
| MX2021016055A (es) | Formulaciones y métodos de parasiticidas de isoxazolina para el tratamiento de la blefaritis. | |
| CA2965129C (en) | Method of treating ocular conditions using varenicline | |
| PH12019500597B1 (en) | CHROMANE, ISOCHROMANE AND DIHYDROISOBENZOFURAN DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE | |
| BR0013793A (pt) | Medicamentos profiláticos e terapêuticos para doenças oftálmicas | |
| EP3231428B1 (en) | Pharmacotherapy for preventing or treating glaucoma | |
| AR046146A1 (es) | Formulaciones farmaceuticas transdermicas para pulverizacion que comprenden un agente activo, un copolimero de vp/va y un vehiculo no acuoso | |
| TW201615180A (zh) | 具有保存功效之醫藥用水性組成物 | |
| MX2024004738A (es) | Formas cristalinas de derivados de quinazolina, preparacion, composicion y uso de estas. | |
| MX2023004565A (es) | Fosfato de vitamina d3 y sales farmaceuticamente aceptables de este, composiciones farmaceuticas que comprenden el compuesto y metodos para preparar el compuesto. | |
| ZA202306096B (en) | Ophthalmic composition containing levofloxacin and ketorolac, method for the preparation and use thereof | |
| JOP20230297A1 (ar) | تركيبة مُعَلَّق مائي توخذ عن طريق الفم تشتمل على مُركَّب كاربامات | |
| US10709702B2 (en) | Treatment of skin disorders by topical administration of VEGF inhibitors | |
| KR102175743B1 (ko) | 피나플록사신 현탁 조성물 | |
| WO2016159351A1 (ja) | 涙腺ドラッグデリバリーシステム | |
| IT202000002296A1 (it) | Formulazioni topiche oftalmiche a base di xantano con ridotta posologia | |
| IL273213B2 (en) | Topical formulations of chloroprocaine | |
| WO2024211244A3 (en) | Novel compounds and uses thereof |